AstraZeneca Announced Earlier It Entered Exclusive Global License Agreement With Dizal For Novel Oral EGFR Inhibitor Zegfrovy For Lung Cancer; AstraZeneca To Pay $600M Upfront, Up To $900M In Milestones, Plus Royalties

뉴스 본문을 불러오고 있어요.

AstraZeneca Announced Earlier It Entered Exclusive Global License Agreement With Dizal For Novel Oral EGFR Inhibitor Zegfrovy For Lung Cancer; AstraZeneca To Pay $600M Upfront, Up To $900M In Milestones, Plus Royalties | 웨이프 WAPE

AstraZeneca Announced Earlier It Entered Exclusive Global License Agreement With Dizal For Novel Oral EGFR Inhibitor Zegfrovy For Lung Cancer; AstraZeneca To Pay $600M Upfront, Up To $900M In Milestones, Plus Royalties

기사 요약

관련 종목

댓글 —